We are pleased to announce that Denis Cavert, our CEO, will present the latest development of our vaccine candidate on 30 October 2024 at 15:55 during the Respiratory session under the title “Metavac®-RSV: in vivo Proof of Concept of first Intranasal vaccine against RSV and HMPV”. Please contact us at admin[at]vaxxel.fr should you which to meet him.